The funding will support the global deployment of xRNA Continuous Manufacturing technologies to LMICs with a strong focus on the development of state-of-the-art inline PAT capabilities and predictive analytics software, the company states. ReciBioPharm’s platform will improve the scalability, quality, and accessibility of RNA-based medicines and will help advance its goal of developing fully integrated, continuous processes across the biomanufacturing industry, they state.

“This grant represents a significant milestone in our commitment to advancing RNA manufacturing technologies that meet FDA standards. We are proud to lead this transformative effort, expanding access to RNA-based solutions for underserved regions,” says Vikas Gupta, President of ReciBioPharm.